The Src pathway and neoangiogenesis have been implicated in prostate cancer progression. In an open-label randomized phase 2 study, no difference was reported in overall survival or time to treatment failure between dasatinib and sunitinib combined with abiraterone after disease progression while receiving abiraterone monotherapy in patients with bone metastatic castration-resistant prostate cancer.
- Androgen-signaling inhibition
- Src pathway
- Targeted agents
- Tumor microenvironment
ASJC Scopus subject areas